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LETTERS TO THE EDITOR 1913Pioglitazone as a novel therapeutic
approach in chronic granuloma-
tous diseaseFIG 1. Chest computed tomography scan before (A) and after (B) pioglita-
zone treatment. Fig 1, A, Large left pulmonary consolidation involving the
inferior lobe and, partly, the dorsal and lingular segments of the superior
lobe, with multiple internal air bronchograms: pneumonia. Similar
pulmonary consolidation is present in the right lung and involves the dorsal
segments of the inferior lobe. Fig 1, B, Remarkable reduction in the areas of
consolidation in the left and right lungs; residual pulmonary lesions are
visible in the left and right inferior lobes.To the Editor:
Chronic granulomatous disease (CGD) is a rare genetic disease
caused by defects in genes encoding the subunits of the
nicotinamide adenine dinucleotide phosphate oxidase complex.1
Accordingly, patients with CGD are affected by life-threatening
bacterial and fungal infections, as well as extensive tissue
granuloma formation. Most frequently, CGD is caused by
mutations in the X-chromosomal CYBB gene, which
encodes for the gp91phox subunit.2 X-chromosome–linked
CGD (X-CGD) generally produces a severe phenotype, with a
mortality rate of 3% to 5% per year despite state-of-the-art pro-
phylaxis and intensive multimodal treatment.3 Hematopoietic
stem cell transplantation (HSCT) represents a curative
treatment for patients with X-CGDwith excellent survival thanks
to recent improvements in HSCT protocols.4 The treatment of
patients without an HLA-matched donor and active infections/
inflammatory complications remains challenging and requires
novel approaches.5
Recently, pioglitazone, a peroxisome proliferator–activated
receptor gamma agonist approved for type 2 diabetes, was
reported in this journal to induce mitochondrial (mt) reactive
oxygen species (ROS) production in mice with X-CGD. Restored
phagocytes demonstrated significantly enhanced killing of
Staphylococcus aureus in vitro and in vivo.6
We report, for the first time, the use of pioglitazone as a novel
therapeutic approach in a 5-month-old boy with X-CGD
experiencing multiple severe infections.
At 1 month of life, the patient developed a cutaneous abscess,
fever, and respiratory distress requiring artificial ventilation in
pediatric intensive care unit. During the hospitalization, he
developed 3 septic shocks, secondary to a peritonsillar abscess,
Candida albicans, and Staphylococcus epidermidis dissemina-
tion, respectively. Thoracic computed tomography scan showed
multiple pulmonary abscesses (Fig 1, A). Because of the
susceptibility to severe infections with organ damage and failure
to thrive, he was investigated for a potential congenital 2016 The Authors. Published by Elsevier, Inc. on behalf of the American Academy of
Allergy,Asthma& Immunology. This is an open access article under theCCBY license
(http://creativecommons.org/licenses/by/4.0/).immunodeficiency. Dihydrorhodamine (DHR) fluorescence
showed impaired response in his peripheral blood and a mutation
of the CYBB gene was identified (c.48311G>T). This mutation,
in literature, is associated with a X-linked CGD form with
undetectable level of gp91phox protein.7
Because of the underlying general conditions of the patient
with persistent pulmonary distress requiring protracted noninva-
sive ventilation, severe delay in neuromuscular development, and
failure to thrive, HSCT was postponed despite availability of an
HLA-identical sibling.
Encouraged by the innovative findings on the effect of
pioglitazone on ROS production and consequent protection
from infection in vitro in human cells and in vivo in an animal
model,6 we sought to investigate, for the first time to our knowl-
edge in children, the potential beneficial effect of oral
pioglitazone. After parent informed consent for off-label use,
pioglitazone was administered at a starting dose of 1 mg/kg and
FIG 2. DHR fluorescence after stimulation with the protein kinase C activator, phorbol 12-myristate
13-acetate (PMA), before and after pioglitazone treatment for the patient (PT) and a healthy donor (HD).
DHR analysis was performed on granulocytes by Phagoburts (BDBiosciences, Milan, Italy) according to
manufacturer’s instructions and analyzed by flow-cytometry. Red line represents the unstimulated
condition; blue line indicates the PMA-stimulated condition. A, DHR results before pioglitazone treatment;
representative histograms for neutrophils show 0.06% response. MFI on total granulocytes (fold increase):
0.90 in patient vs 43.02 in HD. B, DHR results at day110 at target dose demonstrate 12.90% granulocytes
with increased DHR fluorescence. MFI on total granulocytes (fold increase): 2.87 in patient vs 149.7 in HD.
MFI, Mean fluorescent intensity.
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up to 3 mg/kg (15 mg/daily). After 10 days of pioglitazone at
target dose (3 mg/kg), the DHR test showed a percentage of
granulocytes with increased DHR fluorescence (bright fluores-
cent cells 5 12.90%; value before treatment 0.06%; Fig 2, A
and B), albeit at a lower mean fluorescence intensity than normal
donor cells. This effect was maintained in the following weeks
until withdrawal (day130), although at a lower level (day117,
7.55%; day125, 4.86%). Moreover, an overall shift in DHR of
the whole population of patient’s granulocytes was noted after
pioglitazone treatment (for details, see Table E1 in this article’s
Online Repository at www.jacionline.org).
These findings paralleled well with clinical, radiological, and
blood parameters. The patient experienced a progressive improve-
ment in general clinical condition, respiratory parameters, and
function with stable oxygen saturation under neurally adjusted
ventilatory assist-noninvasive ventilation. Lung computed to-
mography scan performed on the day of pioglitazone withdrawal
showed clear improvement (Fig 1, B). White blood cell (WBC)
counts, as well as neutrophil counts, progressively decreased tonormal levels (WBC, 13.9 3 109/L, and neutrophil, 8.2 3 109/
L before pioglitazone; WBC, 6.8 3 109/L, and neutrophil,
2 3 109/L at pioglitazone withdrawal, respectively). C-Reactive
protein level decreased from 24.4 mg/L to 13.1 mg/L before
and after pioglitazone, respectively.
The clinical and radiologic amelioration allowed for HSCT;
pioglitazone was withdrawn and after 1 week, conditioning
regimen based on treosulfan/fludarabine/Thiotepa was adminis-
tered to the patient.8 Graft versus host disease prophylaxis was
conducted through administration of cyclosporin-A and short-
term methotrexate. Neutrophil and platelet engraftment took
place at day117 and 132, respectively. The patient did not
develop signs of graft versus host disease. He is currently at
day1150 after HSCT in good clinical condition with donor
chimerism above 90% on CD141, CD151, and CD31 cells in
peripheral blood. He does not require any respiratory support,
he has a satisfactory oral food intake with weight gain, and he
shows neuromuscular development improvement.
Although observed in a single child, pioglitazone might have
played a role in the protection of the patient from further
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reducing the inflammatory status and by partial restoration of host
defense through induction of mtROS production in his granulo-
cytes. This is also supported by the fact that concomitant
medications were not increased, but rather reduced in
intensity during pioglitazone treatment (for details, see Table
E2 in this article’s Online Repository at www.jacionline.org).
Moreover, corticosteroids were never administered to the
patient, neither before nor during pioglitazone treatment.
Moreover, the patient did not develop any adverse effects related
to pioglitazone administration, confirming the safety of this ther-
apeutic approach. Considering data in female carriers, patients
with HSCT, and improvement after gene therapy,7,9 we speculate
that even an enhancement in DHR fluorescence in a relatively
small population of leukocytes might be the expression of a pro-
tective ROS production. Accordingly, Fernandez-Boyanapalli
et al6 suggest that the mechanism responsible for peroxisome pro-
liferator–activated receptor gamma agonist effect in mice with
CGD is related to increased ROS production by mitochondria in
a subpopulation of neutrophils, monocytes, and inflammatory
macrophages. It remains to be determined which population is
targeted by pioglitazone in vivo.
Presently our observations cannot provide information regarding
long-term effects on mtROS production, but suggest that pioglita-
zone might be used as bridge treatment for these fragile chronic
patients. Fernandez-Boyanapalli et al’s findings and our experience
on the use of pioglitazone provide relevant insights into the
treatment of this rare disease especially for those patients without
a prompt suitable matched donor or for whom the critical disease
conditions force to postpone HSCT.
Further studies conducted through well-designed clinical trials
are warranted to investigate the drug’s precise mechanism of
action, as well as to define the role of pioglitazone in the
therapeutic armamentarium of patients with X-CGD.
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TABLE E1. Percentage of DHR bright and DHR positive granulocytes according to pioglitazone dose*
Time point Pioglitazone dose
DHR bright fluorescent cells
(%)
DHR fluorescent cells
(%)
MFI on total granulocytes
(fold increase)
Before treatment / 0.06 0.07 0.90
5 d of pioglitazone 1 mg/kg 0.20 0.25 0.92
10 d of pioglitazone 2 mg/kg 0.54 0.65 0.97
25 d of pioglitazone (d110) 3 mg/kg 12.90 76.40 2.87
32 d of pioglitazone (d117) 3 mg/kg 7.55 21.00 1.39
40 d of pioglitazone (d125) 3 mg/kg 4.86 6.48 1.29
After HSCT / 94.10 98.30 20.54
MFI, Mean fluorescent intensity.
*The fold increase in MFI is also depicted and is calculated as the ratio between the MFI on total granulocytes after stimulation with PMA and the MFI on unstimulated total
granulocytes.
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TABLE E2. Concomitant medications received by the patient during pioglitazone treatment*
Concomitant medications Dose per day State at pioglitazone start State at pioglitazone stop
Linezolid IV 30 mg/kg Ongoing Stopped 7 d after pioglitazone start
Piperacillin-tazobactam IV 300 mg/kg Ongoing Stopped 10 d after pioglitazone start
Amoxicillin-clavulanic acid PO 50 mg/kg Started 10 d after pioglitazone initiation Ongoing
Trimethoprim-sulphamethoxazole PO 5-25 mg/kg Ongoing Ongoing
Voriconazole IV 8 mg/kg Ongoing Stopped 6 d after pioglitazone start
Itraconazole PO 10 mg/kg Started 6 d after pioglitazone initiation Ongoing
Noninvasive ventilation NA Ongoing Ongoing
IV, Intravenous; NA, not applicable; PO, per os (by mouth).
*Days are expressed in relation to the first day of pioglitazone administration.
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